Neural Stem Cell Transplantation in Multiple Sclerosis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions
Progressive Multiple Sclerosis
Interventions
DRUG

human fetal-derived Neural Stem Cells (hNSCs)

"The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture."

Trial Locations (1)

20132

IRCCS Ospedale San Raffaele, Milan

All Listed Sponsors
collaborator

Fondazione Italiana Sclerosi Multipla

OTHER

lead

IRCCS San Raffaele

OTHER

NCT03269071 - Neural Stem Cell Transplantation in Multiple Sclerosis Patients | Biotech Hunter | Biotech Hunter